CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation

The CIP2A-dependent pathway mediates the tumoricidal effects of erlotinib on NSCLC cells without EGFR mutations in vitro and in vivo. CIP2A may be a novel molecular target against NSCLC for future drug development.